IL1R1 Antibody

What is IL1R1 and why is it an important research target?

IL1R1 (Interleukin 1 Receptor Type I) is a cell surface receptor that mediates the biological effects of IL-1 cytokines. It functions as the primary signaling receptor for IL1A, IL1B, and IL1RN (IL-1 receptor antagonist). When IL-1 binds to IL1R1, it recruits the IL-1 receptor accessory protein (IL1RAP) to form a high-affinity receptor complex that activates NF-kappa-B, MAPK, and other signaling pathways through the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1/2 . IL1R1 is predominantly expressed on T cells, fibroblasts, and endothelial cells, with a molecular weight of approximately 65.4 kDa . Its central role in mediating inflammatory responses makes it a critical target for studying immune regulation, inflammatory diseases, and potential therapeutic interventions.

What types of IL1R1 antibodies are available for research applications?

Several types of IL1R1 antibodies are available for research, including:

• Monoclonal antibodies: Highly specific antibodies derived from a single B-cell clone, such as the mouse monoclonal 4D2D12 targeting amino acids 226-352 of IL1R1 .

• Polyclonal antibodies: Antibodies derived from multiple B-cell clones that recognize different epitopes on IL1R1, such as rabbit polyclonal antibodies targeting various regions (e.g., aa 1-250, aa 226-318) .

• Conjugated antibodies: IL1R1 antibodies conjugated with fluorophores (e.g., Alexa Fluor 647) for flow cytometry and fluorescence microscopy applications .

• Neutralizing antibodies: Functional antibodies that can block IL-1 binding to IL1R1, such as those measured by their ability to neutralize IL-1β-induced CXCL1/GRO alpha secretion in cell lines .

The choice of antibody depends on the specific application, with monoclonals preferred for consistent detection of specific epitopes and polyclonals useful for detecting proteins in denatured states or when higher sensitivity is required.

What are the validated applications for IL1R1 antibodies?

IL1R1 antibodies have been validated for multiple applications, with performance varying by antibody clone and source:

Researchers should note that individual antibodies may perform differently across applications, and validation in your specific experimental system is always recommended .

How do IL1R1 antibodies compare to bioassays for studying IL-1 signaling?

IL1R1 antibodies offer several advantages over traditional bioassays when studying IL-1 signaling:

Antibody-based assays such as ELISA and radioimmunoassays circumvent many limitations of bioassays, which are often difficult to perform, lack specificity due to competing cytokines, and have reduced sensitivity in complex biological fluids due to non-specific protein binding and the presence of IL-1 antagonists. This makes antibody-based approaches more suitable for clinical specimens and complex biological samples .

Monoclonal antibodies and polyclonal antisera have enabled researchers to identify functionally important regions of the IL-1 molecule and monitor post-translational processing, including biologically inactive moieties that wouldn't be detected in functional assays. This has led to the development of novel cell blot procedures and other advanced detection methods that provide more comprehensive insights into IL-1 signaling dynamics .

What are the optimal sample preparation methods for detecting IL1R1 in different applications?

The optimal sample preparation depends on the application and the nature of the sample:

For Western Blotting:

• Extract proteins using RIPA buffer supplemented with protease inhibitors

• Include phosphatase inhibitors if studying phosphorylated forms of IL1R1 (e.g., pTyr496)

• Denature samples at 95°C for 5 minutes in reducing buffer

• Load 20-50 μg of total protein per lane on SDS-PAGE gels

• Transfer to PVDF or nitrocellulose membranes at lower voltages (e.g., 30V overnight) to ensure complete transfer of the 65.4 kDa protein

For Immunohistochemistry:

• Fix tissues in 10% neutral buffered formalin for 24-48 hours

• Perform heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Block endogenous peroxidase activity with 3% hydrogen peroxide

• Use protein blocking solution to reduce background staining

• Incubate with primary antibody at optimized dilutions (typically 1:100 to 1:500) overnight at 4°C

For Flow Cytometry:

• Harvest cells and wash in cold PBS with 1% BSA

• Fix cells with 2% paraformaldehyde if intracellular staining is required

• For surface staining, maintain cells in non-fixed state

• Block Fc receptors to reduce non-specific binding

• Stain with fluorophore-conjugated IL1R1 antibodies at manufacturer-recommended dilutions (typically 5-10 μL per 1×10^6 cells)

Optimization for each specific antibody and sample type is essential for reliable results.

How can I validate the specificity of an IL1R1 antibody?

Validating antibody specificity is crucial for reliable results. Several approaches can be used:

• Positive and negative controls: Test the antibody on cell lines or tissues known to express or lack IL1R1. T cells, fibroblasts, and endothelial cells typically express IL1R1 and can serve as positive controls .

• Knockdown/knockout validation: Compare antibody reactivity in wild-type samples versus samples where IL1R1 has been knocked down using siRNA or knocked out using CRISPR-Cas9. A specific antibody should show significantly reduced or absent signal in knockdown/knockout samples.

• Peptide competition assay: Pre-incubate the antibody with excess recombinant IL1R1 protein or the immunizing peptide before applying to samples. This should abolish specific binding if the antibody is truly specific.

• Multiple antibody validation: Test multiple antibodies targeting different epitopes of IL1R1. Consistent patterns across different antibodies suggest specific detection.

• Western blot molecular weight verification: Confirm that the detected band corresponds to the expected molecular weight of IL1R1 (approximately 65.4 kDa) .

• Cross-species reactivity: If the antibody claims reactivity to multiple species, verify consistent detection patterns across these species, accounting for known variations in expression patterns or molecular weight.

Documentation of validation experiments should be maintained for publication purposes and experimental reproducibility.

What factors affect IL1R1 detection sensitivity in different experimental systems?

Several factors can influence the sensitivity of IL1R1 detection:

• Antibody selection: Monoclonal antibodies typically offer higher specificity but may have lower sensitivity than polyclonal antibodies. The specific epitope targeted also matters—antibodies targeting conserved regions may provide more consistent results across species .

• Expression levels: IL1R1 expression can vary dramatically between cell types and under different conditions. T cells, fibroblasts, and endothelial cells typically express higher levels compared to other cell types, making detection more straightforward .

• Sample preparation: Incomplete protein extraction, over-fixation of tissues, or inappropriate antigen retrieval can significantly reduce detection sensitivity. For membrane proteins like IL1R1, detergent selection in lysis buffers is particularly important .

• Signal amplification: For low-abundance detection, consider using signal amplification systems like tyramide signal amplification (TSA) for IHC/ICC or biotin-streptavidin systems for ELISA and flow cytometry .

• Detection method: Chemiluminescence typically offers higher sensitivity than colorimetric detection for Western blotting, while fluorescence-based detection may be preferred for multiplex applications.

• Buffer conditions: pH, salt concentration, and the presence of detergents can all affect antibody binding. Following manufacturer's recommendations for buffer composition is essential for optimal sensitivity .

Researchers should conduct pilot experiments to determine the optimal conditions for their specific experimental system.

How can IL1R1 antibodies be used to study the IL-1 axis in T follicular helper (Tfh) and T follicular regulatory (Tfr) cell responses?

IL1R1 antibodies have proven valuable in elucidating the role of the IL-1 axis in regulating germinal center responses through Tfh and Tfr cells:

Methodological Approach:

• Flow cytometry panels: Use fluorophore-conjugated IL1R1 antibodies in multicolor flow cytometry panels to identify IL1R1-expressing Tfh cells. This has revealed that most Tfh cells from germinal centers express IL1R1, while Tfr cells express IL1R2 and IL1Ra, suggesting a regulatory mechanism .

• Functional assays: Neutralizing IL1R1 antibodies can be used in functional assays to block IL-1-mediated activation of Tfh cells. These studies have shown that IL-1β directly stimulates Tfh cells to produce IL-4 and IL-21, key cytokines for B cell help .

• In vivo models: Administration of IL1R1 antibodies or IL-1Ra (Anakinra) in experimental animals during immunization can be used to assess the impact of IL-1 signaling blockade on Tfh cell expansion and germinal center formation. This approach has demonstrated that IL-1β induces proliferation of Tfh cells in vivo, while Anakinra significantly reduces Tfh cell proportions .

• Co-culture systems: IL1R1 antibodies can be used in Tfh-B cell or Tfh-Tfr-B cell co-culture systems to understand how IL-1 signaling impacts the helper function of Tfh cells and the suppressive function of Tfr cells. These experiments have shown that Tfr cells can suppress Tfh activation to the same extent as recombinant IL-1Ra, suggesting IL-1 pathway involvement in Tfr suppressive function .

This research direction has revealed a crucial IL-1 axis regulating germinal center responses, suggesting a dual regulation system: IL-2 regulating Treg and effector T cells outside germinal centers, and IL-1 regulating Tfh and Tfr cells inside germinal centers .

What approaches can be used to study IL1R1 signaling complexes and downstream pathways?

Studying IL1R1 signaling complexes requires specialized techniques to capture transient protein interactions and downstream signaling events:

• Co-immunoprecipitation with IL1R1 antibodies: Use IL1R1 antibodies for immunoprecipitation followed by Western blotting or mass spectrometry to identify interacting partners. This approach has identified the association of IL1R1 with IL1RAP and adapter molecules such as TOLLIP, MYD88, and IRAK1/2 .

• Proximity labeling approaches: Techniques like BioID or APEX2 proximity labeling, where IL1R1 is fused to a biotin ligase, can identify proteins in close proximity to IL1R1 upon IL-1 stimulation.

• Phospho-specific antibodies: Antibodies targeting phosphorylated forms of IL1R1 (such as pTyr496) or downstream signaling molecules can be used to track signaling cascades activated by IL-1 binding .

• Reporter assays: NF-κB or MAPK pathway reporter constructs can be used to quantify downstream signaling activation in response to IL-1 stimulation and assess the impact of IL1R1 antibody-mediated neutralization.

• Cell-based signaling assays: Systems like the HT-29 human colon adenocarcinoma cell line, which secretes CXCL1/GRO alpha in response to IL-1β stimulation, can be used to measure IL1R1 antibody neutralizing capacity .

• Single-cell signaling analysis: Flow cytometry or mass cytometry with phospho-specific antibodies can be used to assess IL-1 signaling at the single-cell level, revealing cell population heterogeneity in response to IL-1.

These approaches have collectively established that IL1R1 signaling involves the formation of a complex with IL1RAP and subsequent recruitment of intracellular signaling molecules, ultimately activating NF-κB and MAPK pathways that drive inflammatory gene expression .

How do IL1R1 and IL1R2 differ functionally, and how can antibodies help distinguish their roles?

IL1R1 and IL1R2 have distinct functions in IL-1 signaling, and specific antibodies are essential for differentiating their roles:

Functional Differences:

• IL1R1: An 80 kDa transmembrane protein expressed predominantly on T cells, fibroblasts, and endothelial cells. It forms a signaling complex with IL1RAP when bound to IL-1α or IL-1β, mediating all known IL-1 biological responses through intracellular signaling .

• IL1R2: A 68 kDa transmembrane protein found on B lymphocytes, neutrophils, monocytes, large granular leukocytes, and endothelial cells. It has a short cytoplasmic domain and does not transduce IL-1 signals. Both membrane-bound and soluble forms of IL1R2 function as decoys that bind IL-1 without signaling, thereby inhibiting IL-1 action .

Methodological Approaches Using Antibodies:

• Selective detection: Use antibodies specific to either IL1R1 or IL1R2 in flow cytometry or immunohistochemistry to characterize the expression patterns on different cell populations. This has revealed that Tfh cells predominantly express IL1R1, while Tfr cells express IL1R2 .

• Function-blocking experiments: Apply neutralizing antibodies specific to IL1R1 or IL1R2 to distinguish their respective contributions to IL-1 responses. IL1R1-blocking antibodies should inhibit IL-1 signaling, whereas IL1R2-blocking might potentially enhance IL-1 effects by preventing decoy receptor function.

• Soluble receptor detection: Use ELISA assays with antibodies specific to the extracellular domains of IL1R1 or IL1R2 to measure soluble receptor levels in biological fluids. This approach has shown that soluble IL1R2 serves as a natural antagonist of IL-1 action .

• Co-localization studies: Employ differentially labeled antibodies against IL1R1 and IL1R2 in confocal microscopy to examine their cellular and subcellular distribution, potentially revealing distinct localization patterns relevant to their different functions.

These approaches have established that IL1R1 and IL1R2 form a regulatory system for IL-1 signaling, with IL1R1 mediating signaling and IL1R2 serving as a decoy to limit excessive IL-1 activity. This understanding is particularly relevant in contexts like germinal center reactions, where the balance between these receptors on Tfh and Tfr cells appears to regulate humoral responses .

What are common pitfalls when using IL1R1 antibodies and how can they be addressed?

Researchers frequently encounter several challenges when working with IL1R1 antibodies:

• Non-specific binding: This is particularly problematic in IHC and flow cytometry applications.

  • Solution: Implement stringent blocking protocols using 5-10% normal serum from the same species as the secondary antibody. For flow cytometry, include Fc receptor blocking reagents to prevent non-specific binding to Fc receptors on immune cells .

• Inconsistent detection across applications: An antibody that works well for Western blotting might fail in IHC or flow cytometry.

  • Solution: Select antibodies validated for your specific application. Consider using different antibodies for different applications rather than expecting one antibody to perform optimally across all techniques .

• Cross-reactivity with related receptors: Some antibodies may cross-react with IL1R2 or other IL-1 family receptors.

  • Solution: Validate antibody specificity using knockout/knockdown controls or competing peptides. When available, use antibodies that target regions with low sequence homology between receptor family members .

• Variable epitope accessibility: In fixed tissues or native protein conformations, epitopes may be masked.

  • Solution: For IHC, optimize antigen retrieval methods (citrate versus EDTA buffers, pH variations, retrieval time). For flow cytometry of surface proteins, avoid fixation or use mild fixation protocols .

• Batch-to-batch variation: Different lots of the same antibody can show performance variations.

  • Solution: Validate each new lot against your established positive controls. Consider purchasing larger lots for long-term projects to maintain consistency .

• Detection of cleaved/soluble forms: IL1R1 can exist in membrane-bound and soluble forms.

  • Solution: Choose antibodies that can distinguish between these forms or use complementary approaches (e.g., surface staining for flow cytometry plus ELISA for soluble forms in supernatants) .

Maintaining detailed protocols and validation data helps track and resolve these issues across experiments.

How should I interpret contradictory results when using different IL1R1 antibodies?

Contradictory results with different IL1R1 antibodies are not uncommon and require systematic investigation:

• Epitope mapping analysis: Different antibodies target different epitopes on IL1R1, which may be differentially accessible depending on protein conformation, fixation method, or the presence of interacting proteins. Compare the epitope regions targeted by each antibody (e.g., aa 1-250 versus aa 226-318) to understand potential differences in detection capabilities .

• Application-specific optimization: Each antibody may require distinct optimization for different applications. For example, an antibody showing strong signals in Western blotting but weak signals in IHC may need different dilutions, incubation times, or antigen retrieval methods for optimal performance across applications .

• Cross-validation with non-antibody methods: Supplement antibody-based detection with functional assays or mRNA expression analysis. For example, validate protein expression patterns using RT-PCR or RNA-seq data for IL1R1 transcripts, or use reporter cell lines to confirm functional IL-1 signaling .

• Species-specific considerations: If working across species, ensure that antibodies are truly cross-reactive with your species of interest. Even antibodies claimed to be cross-reactive may show different affinities across species due to sequence variations .

• Biological variation vs. technical artifacts: Determine whether contradictory results reflect true biological differences (e.g., different IL1R1 isoforms or post-translational modifications) versus technical artifacts. Using multiple antibodies targeting different regions can help distinguish these possibilities .

When publishing results, transparently report which antibodies were used, their validation methods, and acknowledge potential limitations in interpretation if different antibodies yield different results.

How can I quantitatively analyze IL1R1 expression data from different experimental approaches?

Quantitative analysis of IL1R1 expression requires application-specific approaches:

For Western Blotting:

• Use densitometry software (ImageJ, ImageLab) to quantify band intensity

• Normalize to loading controls (β-actin, GAPDH)

• Present data as relative expression (fold change) compared to control samples

• Statistical analysis should compare multiple independent experiments (n≥3)

For Flow Cytometry:

• Report both percentage of IL1R1-positive cells and mean/median fluorescence intensity (MFI)

• Use fluorescence minus one (FMO) controls to set positive/negative boundaries

• For comparing expression levels, calculate the specific staining index: (MFI of sample - MFI of isotype control)/standard deviation of isotype control

• Present data as histograms overlaid with controls or as scatter plots with statistical analysis

For Immunohistochemistry:

• Use digital image analysis software to quantify staining intensity and distribution

• Apply consistent thresholds across all samples

• Consider both staining intensity (0-3+ scale) and percentage of positive cells to calculate H-scores or quick scores

• For spatial analysis, measure IL1R1 expression in relation to tissue structures or other markers

For ELISA:

• Generate standard curves using recombinant IL1R1 protein of known concentration

• Ensure samples fall within the linear range of detection

• Calculate absolute concentrations based on standard curves

• Present data as concentration per volume or normalized to total protein

When comparing data across methods, acknowledge the different aspects of expression being measured (e.g., total protein, surface expression, soluble forms) and interpret accordingly.

How are IL1R1 antibodies being used to investigate the role of IL-1 signaling in autoimmune diseases?

IL1R1 antibodies are enabling researchers to uncover the complex roles of IL-1 signaling in autoimmune pathogenesis:

• Tissue-specific expression analysis: Immunohistochemistry with IL1R1 antibodies is being used to map receptor expression patterns in affected tissues from autoimmune disease patients compared to healthy controls. This has revealed altered expression patterns in conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease .

• Cellular phenotyping: Flow cytometry with IL1R1 antibodies is helping characterize immune cell subsets that respond to IL-1 in autoimmune contexts. Recent studies have shown that IL1R1 expression on Tfh cells may contribute to excessive antibody production in systemic lupus erythematosus and other antibody-mediated autoimmune diseases .

• Mechanistic studies: Neutralizing IL1R1 antibodies in ex vivo cultures of patient samples are being used to assess the contribution of IL-1 signaling to pathogenic cellular responses. These approaches have demonstrated that blocking IL-1 signaling can reduce inflammatory cytokine production and pathogenic Tfh cell activation .

• Biomarker development: ELISA assays using IL1R1 antibodies are being developed to measure soluble receptor levels in patient serum as potential biomarkers for disease activity or treatment response.

These research approaches are significant because they suggest that targeting the IL-1 pathway could represent an important therapeutic strategy for many autoimmune diseases. By reducing inflammation and directly inhibiting pathogenic antibody responses, IL-1 pathway blockade could potentially address both symptoms and underlying disease mechanisms .

What are the latest techniques for studying IL1R1 dynamics and trafficking using antibody-based approaches?

Advanced imaging and biochemical techniques with IL1R1 antibodies are revealing new insights into receptor dynamics:

• Live-cell imaging: Conjugating IL1R1 antibodies to quantum dots or other stable fluorophores enables real-time tracking of receptor movement in living cells. This approach has been used to monitor receptor internalization and recycling following ligand binding.

• Super-resolution microscopy: Techniques like STORM, PALM, or STED microscopy with fluorescently labeled IL1R1 antibodies can visualize receptor nanoclusters and colocalization with signaling partners at resolutions below the diffraction limit.

• Fluorescence resonance energy transfer (FRET): Dual-labeled antibody approaches targeting IL1R1 and potential interaction partners can detect molecular proximity (within 10 nm) indicative of protein-protein interactions.

• Receptor internalization assays: Differential labeling of surface versus internalized receptors using pH-sensitive fluorophores conjugated to IL1R1 antibodies allows quantification of receptor endocytosis rates following stimulation.

• Pulse-chase antibody labeling: Sequential labeling with different fluorophore-conjugated IL1R1 antibodies can track newly synthesized versus existing receptor pools, providing insight into receptor turnover rates.

• Antibody-based proximity labeling: Methods like antibody-directed enzyme prodrug therapy (ADEPT) adapted for research use can selectively label proteins in the vicinity of IL1R1, identifying the receptor's local interactome.

These techniques are uncovering how IL1R1 trafficking and localization contribute to signaling regulation, with implications for understanding both normal immune responses and pathological conditions where IL-1 signaling is dysregulated .

How can IL1R1 antibodies contribute to developing new therapeutic approaches for inflammatory diseases?

IL1R1 antibodies are instrumental in multiple aspects of therapeutic development:

• Target validation: Neutralizing IL1R1 antibodies in preclinical disease models help establish the therapeutic potential of IL-1 pathway blockade. Research using these approaches has demonstrated efficacy in models of autoimmunity, inflammatory bowel disease, and other inflammatory conditions .

• Biomarker identification: Quantitative assessment of IL1R1 expression using antibody-based methods (IHC, flow cytometry, ELISA) helps identify patient subgroups most likely to benefit from IL-1-targeted therapies. This facilitates patient stratification for clinical trials and personalized medicine approaches.

• Mechanism of action studies: IL1R1 antibodies enable detailed investigation of how existing IL-1 pathway antagonists (like Anakinra) exert their effects. Flow cytometry with IL1R1 antibodies has shown that Anakinra reduces Tfh cell proportions similar to the suppressive effect of Tfr cells, providing mechanistic insight into its therapeutic action .

• Therapeutic antibody development: Research-grade IL1R1 antibodies serve as starting points for developing therapeutic antibodies. Characterization of epitope specificity, neutralizing capacity, and binding kinetics helps identify candidates for further development.

• Combination therapy assessment: IL1R1 antibodies facilitate studies of how IL-1 blockade might synergize with other immunomodulatory approaches. For example, combined blockade of IL-1 and IL-6 might more effectively suppress pathogenic Tfh responses than either approach alone .

The expanding understanding of IL-1's role in regulating humoral immunity through Tfh and Tfr cells suggests that IL-1 pathway-targeting strategies could address not only inflammation but also pathogenic antibody production in autoimmune diseases, representing a dual mechanism of action with potentially greater therapeutic efficacy .